{
    "id": "347c906c-7fbd-c0b2-e063-6394a90acb4b",
    "indications": {
        "text": "naltrexone hydrochloride tablets usp 50 mg indicated treatment alcohol dependence blockade effects exogenously administered opioids . naltrexone hydrochloride tablets usp 50 mg shown provide therapeutic benefit except part appropriate plan management addictions .",
        "doid_entities": [
            {
                "text": "alcohol dependence (DOID:0050741)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050741"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "reduce risk precipitated withdrawal patients dependent opioids , exacerbation preexisting subclinical withdrawal syndrome , opioid-dependent patients , including treated alcohol dependence , opioid-free ( including tramadol ) starting naltrexone hydrochloride treatment . opioid-free interval minimum 7 10 days recommended patients previously dependent short-acting opioids . switching buprenorphine , buprenorphine/naloxone , methadone systematically collected data specifically address switch buprenorphine methadone naltrexone hydrochloride ; however , review postmarketing case reports indicated patients may experience severe manifestations precipitated withdrawal switched opioid agonist therapy opioid antagonist therapy ( ) . patients transitioning buprenorphine methadone may vulnerable precipitation withdrawal symptoms long 2 weeks . healthcare providers prepared manage withdrawal symptomatically non-opioid medications .",
        "doid_entities": [
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "alcohol dependence (DOID:0050741)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050741"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "naltrexone hydrochloride tablets usp 50 mg yellow coloured , oval , biconvex , film-coated tablets breakline one side '50 ' debossed side . available ndc : 70518-1146-00 ndc : 70518-1146-01 packaging : 30 1 blisteer pack packaging : 30 1 blister pack store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature ] . dispense tight container . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "naltrexone hydrochloride contraindicated patients receiving opioid analgesics . patients currently dependent opioids , including currently maintained opiate agonists ( e.g . , methadone ) partial agonists ( e.g . , buprenorphine ) patients acute opioid withdrawal ( ) . individual failed naloxone challenge test positive urine screen opioids . individual history sensitivity naltrexone hydrochloride components product.it known cross-sensitivity naloxone phenanthrene containing opioids .",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134687"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Naltrexone Hydrochloride",
    "effectiveTime": "20250506",
    "indications_original": "Naltrexone hydrochloride tablets USP 50 mg is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.\n                  Naltrexone hydrochloride tablets USP 50 mg has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.",
    "contraindications_original": "To reduce the risk of precipitated withdrawal in patients dependent on opioids, or exacerbation of a preexisting subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting naltrexone hydrochloride treatment. An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids.\n                  \n                     Switching from Buprenorphine, Buprenorphine/Naloxone, or Methadone\n                  \n                  There are no systematically collected data that specifically address the switch from buprenorphine or methadone to naltrexone hydrochloride; however, review of postmarketing case reports have indicated that some patients may experience severe manifestations of precipitated withdrawal when being switched from opioid agonist therapy to opioid antagonist therapy (see\n \n  \n                        WARNINGS\n                     ).Patients transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal symptoms for as long as 2 weeks. Healthcare providers should be prepared to manage withdrawal symptomatically with non-opioid medications.",
    "warningsAndPrecautions_original": "Naltrexone hydrochloride tablets USP 50 mg yellow coloured, oval, biconvex, film-coated tablets with breakline on one side and '50' debossed on the other side. Available in\n                  \n                  NDC: 70518-1146-00\n                  NDC: 70518-1146-01\n                  PACKAGING: 30 in 1 BLISTEER PACK\n                  PACKAGING: 30 in 1 BLISTER PACK \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature].\n                  Dispense in a tight container.\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Naltrexone hydrochloride is contraindicated in\n                  \n                     Patients receiving opioid analgesics.\n                     Patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone ) or partial agonists (e.g., buprenorphine)\n                     Patients in acute opioid withdrawal (see\n  \n   \n                           WARNINGS\n                        ).\n \n  \n                     Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids.\n                     Any individual with a history of sensitivity to naltrexone hydrochloride or any other components of this product.It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids.",
    "drug": [
        {
            "name": "Naltrexone Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134687"
        }
    ]
}